Genprex

Monthly Archives: December 2020

Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants

Proceeds will add resources for the Company’s Acclaim-1 and Acclaim-2 clinical trials in lung cancer, as well as its pre-clinical programs in cancer and diabetes

Read More

Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants

Genprex has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor for the purchase and sale of 3,116,884 shares of its common stock at a purchase price of $3.85 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Read More

Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Major Manufacturing Milestone Positions the Company for Success In the Lung Cancer Therapeutics Market, Expected to Grow to $26.3 Billion by 2023

Read More

Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy

Successful Completion of Engineering Batch with Transfer from Research Institution to Commercial Contract Development and Manufacturing Organizations with Clinical Production Underway

Read More

Genprex to Present at the Benzinga Global Small Cap Conference on December 8

Presentation to Highlight the Company’s Recent Progress on its Upcoming Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Read More